SCHEMBL22169802

SCHEMBL22169802

CC(NC(=O)C(C)(C)C)C1CCOCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
MMP2 P08253 2/20 0.38
CA9 Q16790 2/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
EPHX2 P34913 1/20 0.35
SIGMAR1 Q99720 1/20 0.33
PIK3CD O00329 1/20 0.33
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RIPK1 Q13546 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
EGLN1 Q9GZT9 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22169795 0.90 MAPK1 (0.34) CA12CA1CA2MMP2CA9
SCHEMBL26252000 0.87 EPHX2 (0.43) CA12CA1CA2MMP2CA9
SCHEMBL15116456 0.83 CA12 (0.53) CA12CA1CA2MMP2CA9
SCHEMBL19836585 0.81 CA12 (0.56) CA12CA1CA2MMP2CA9
SCHEMBL19652079 0.81 CA12 (0.56) CA12CA1CA2MMP2CA9
SCHEMBL12184827 0.79 CA12 (0.41) CA12CA1CA2MMP2CA9
SCHEMBL26658344 0.79 CA12 (0.41) CA12CA1CA2MMP2CA9
SCHEMBL6119950 0.79 EPHX2 (0.41) CA12CA1CA2MMP2CA9
SCHEMBL14864803 0.76 CA12 (0.42) CA12CA1CA2MMP2CA9
SCHEMBL12174947 0.76 CA12 (0.42) CA12CA1CA2MMP2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11220506-B2 Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors BEIGENE, LTD. (KY) 2022-01-11 US disclosed
US-20200207774-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207774-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS PIK3CD, PIK3R5, PIK3CA CA12 4800/4885CA1 4355/4885CA2 2243/4885
US-11220506-B2 Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors PIK3CD, PIK3R5, PIK3CA CA12 4800/4885CA1 4355/4885CA2 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.